Statements (14)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:natural_killer_cell_therapy
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:cellType |
allogeneic NK cells
|
| gptkbp:clinicalTrialPhase |
Phase 1
|
| gptkbp:developedBy |
gptkb:Nkarta_Therapeutics
|
| gptkbp:engineeredFeature |
chimeric antigen receptor (CAR)
|
| gptkbp:indication |
gptkb:acute_myeloid_leukemia
myelodysplastic syndrome |
| gptkbp:mechanismOfAction |
engineered NK cells expressing NKG2D CAR
|
| gptkbp:target |
NKG2D ligands
|
| gptkbp:usedFor |
gptkb:immunotherapy
|
| gptkbp:bfsParent |
gptkb:Nkarta_Therapeutics
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
NKX101
|